posters
CLINICAL MEASUREMENT, DRUG DEVELOPMENT AND ENVIRONMENT
CLINICAL MEASUREMENT
| | Contribution of Psychosocial Factors to Appetite in MND Sally Neville |
| | Radiological and Volumetric Callosal Abnormalities as a Marker of ALS Pathology Sienna Berte |
DRUG DEVELOPMENT
| | MisfoldUbL: A genetic therapy targeting misfolded SOD1 Christen Chisolm |
| | Advancing ALS with Human-Induced Microglia Dr Hazel Quek |
| | Developing a brain-penetrating antisense therapy for SOD1-mediated MND Matteo Pitteri |
| | Effects of antiretroviral therapy, Triumeq, on motor behaviour, TDP-43 expression and immune response in a motor neuron disease mouse model Megan Dubowsky |
| | A high-throughput flow cytometry drug screen to discover new treatments for motor neurone disease. Dr Nicholas Geraghty |
| | Characterising Potential Therapeutics in a TDP-43 Overexpression Cell Model of Motor Neurone Disease Nicole Miles |
| | Polytherapy to aid SOD1 maturation in familial ALS. Mikayla Brown |
| | Preclinical assessment of GHRP3 as a therapy in ALS Hao Wang |
ENVIRONMENT
| iPSC clinical trials â - population wide drug screening of patient-derived motor neurons for MND/ALS Christopher Bye |
© Copyright 2023 Somerset Event Management